{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:06:53Z","timestamp":1740128813563,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Merck Sharp and Dohme, LLC","award":["IIS# 59557"],"award-info":[{"award-number":["IIS# 59557"]}]},{"name":"Plan Nacional de I + D + I"},{"name":"Fondo"},{"name":"Europeo de Desarrollo Regional","award":["RD16\/0025\/0040","RD16\/0025\/0026"],"award-info":[{"award-number":["RD16\/0025\/0040","RD16\/0025\/0026"]}]},{"name":"Fundacion Progreso y Salud"},{"name":"Junta de Andalucia","award":["PI-0550-2017","FIS PI 18\/00819","FIS PI 22\/00882"],"award-info":[{"award-number":["PI-0550-2017","FIS PI 18\/00819","FIS PI 22\/00882"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR22\/00055","CM21\/00060"],"award-info":[{"award-number":["JR22\/00055","CM21\/00060"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Limited data are available regarding the susceptibility of the reverse transcriptase V106 polymorphism to doravirine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Doravirine susceptibility was measured in site-directed mutants (SDMs) containing V106I, V106A, V106M, and Y188L mutations in subtype B (NL4-3, HXB2) and CRF02_AG background and in recombinant viruses with RT harboring V106I alone derived from 50 people with HIV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HIV-1 B subtype was detected in 1523 of 2705 cases. Prevalence of V106I was 3.2% in B and 2.5% in non-B subtypes, and was higher in subtype F (8.1%) and D (14.3%). Fold-changes (FC) in susceptibility for SDMs were below doravirine biological cutoff (3.0) for V106I, but not for V106A, V106M, and Y188L. Clinically derived viruses tested included 22 B (median FC, 1.2; interquartile range [IQR], 0.9\u20131.6) and 28 non-B subtypes (median FC, 1.8; IQR, 0.9\u20133.0). Nine (18%) viruses showed FC values equal or higher than the doravirine biological FC cutoff.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The prevalence of the HIV-1 RT V106I polymorphism in MeditRes HIV consortium remains low, but significantly more prevalent in subtypes D and F. V106I minimally decreased the susceptibility to doravirine in SDMs and most clinical isolates. Reduced susceptibility seems to occur at increased frequency in subtype F1; however, the clinical impact remains to be investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT04894357.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae010","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T15:07:24Z","timestamp":1704985644000},"page":"1796-1802","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes"],"prefix":"10.1093","volume":"229","author":[{"given":"Federica","family":"Giammarino","sequence":"first","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-858X","authenticated-orcid":false,"given":"Adolfo","family":"de Salazar","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Hospital Universitario Clinico San Cecilio , Granada , Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria (ibs.Granada) , Granada , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Instituto de Salud Carlos III, Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Malet","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Vi\u00f1uela","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Hospital Universitario Clinico San Cecilio , Granada , Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria (ibs.Granada) , Granada , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Instituto de Salud Carlos III, Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2057-2730","authenticated-orcid":false,"given":"Ana","family":"Fuentes","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Hospital Universitario Clinico San Cecilio , Granada , Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria (ibs.Granada) , Granada , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Instituto de Salud Carlos III, Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9934-377X","authenticated-orcid":false,"given":"Francesco","family":"Saladini","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Bartolini","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Service de Virologie, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME, UMR 1137, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bichat-Claude Bernard , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3378-250X","authenticated-orcid":false,"given":"Sidonie","family":"Lambert-Niclot","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Saint-Antoine , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-0903","authenticated-orcid":false,"given":"Gaetana","family":"Sterrantino","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Florence , Florence , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Colao","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology and Virology, Careggi Hospital , Florence , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Micheli","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Virology, and Bioemergencies, Sacco University Hospital , Milan , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Bertoli","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, University Hospital Tor Vergata , Rome , Italy"},{"name":"Department of Experimental Medicine, University of Rome Tor Vergata , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavinia","family":"Fabeni","sequence":"additional","affiliation":[{"name":"Virology and Biosafety Laboratories Unit, Lazzaro Spallanzani-IRCCS, National Institute for Infectious Diseases , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Teyssou","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-4736","authenticated-orcid":false,"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Service, Instituto de Investigaci\u00f3n, Hospital 12 de Octubre , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5888-7706","authenticated-orcid":false,"given":"Iker","family":"Falces-Romero","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Instituto de Salud Carlos III, Madrid , Spain"},{"name":"Clinical Microbiology Service, Hospital La Paz , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Aguilera","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Service, Hospital Cl\u00ednico Universitario de Santiago, Instituto de Investigaci\u00f3n Sanitaria de Santiago (IDIS) , Santiago de Compostela , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perpetua","family":"Gomes","sequence":"additional","affiliation":[{"name":"Egas Moniz Center for Interdisciplinary Research, Egas Moniz School of Health and Science , Almada , Portugal"},{"name":"Laborat\u00f3rio de Biolog\u00eda Molecular, Centro Hospitalar Lisboa Ocidental-Hospital Egas Moniz , Lisboa , Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6167-7152","authenticated-orcid":false,"given":"Dimitrios","family":"Paraskevis","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Epidemiology, and Medical Statistics, National and Kapodistrian University of Athens , Athens , Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria M","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata , Rome , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Genevieve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Moreno","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Instituto de Salud Carlos III, Madrid , Spain"},{"name":"National Centre for Epidemiology, Institute of Health Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-781X","authenticated-orcid":false,"given":"Federico","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Hospital Universitario Clinico San Cecilio , Granada , Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria (ibs.Granada) , Granada , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC) , Instituto de Salud Carlos III, Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"2024061323521843800_jiae010-B1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2024061323521843800_jiae010-B2","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society\u2013USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"author":"European AIDS Clinical Society","key":"2024061323521843800_jiae010-B3"},{"key":"2024061323521843800_jiae010-B4","doi-asserted-by":"crossref","first-page":"e25611","DOI":"10.1002\/jia2.25611","article-title":"HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates","volume":"23","author":"Rhee","year":"2020","journal-title":"J Intern AIDS Soc"},{"key":"2024061323521843800_jiae010-B5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061323521843800_jiae010-B6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus\u20131 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024061323521843800_jiae010-B7","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2024061323521843800_jiae010-B8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/jac\/dky464","article-title":"Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients","volume":"74","author":"Soulie","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024061323521843800_jiae010-B9","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/jac\/dkaa009","article-title":"The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations","volume":"75","author":"Guerrero-Beltr\u00e1n","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024061323521843800_jiae010-B10","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/cid\/ciac972","article-title":"Transmitted drug resistance to integrase-based first-line human immunodeficiency virus antiretroviral regimens in Mediterranean Europe","volume":"76","author":"De Salazar","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024061323521843800_jiae010-B11","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1093\/jac\/dku095","article-title":"New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors","volume":"69","author":"Malet","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2024061323521843800_jiae010-B12","doi-asserted-by":"crossref","first-page":"106737","DOI":"10.1016\/j.ijantimicag.2023.106737","article-title":"Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO registry","volume":"61","author":"Saladini","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2024061323521843800_jiae010-B13","doi-asserted-by":"crossref","first-page":"e22206","DOI":"10.1002\/jcla.22206","article-title":"Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV -1 protease, reverse transcriptase, and integrase inhibitors","volume":"32","author":"Saladini","year":"2018","journal-title":"J Clin Lab Anal"},{"key":"2024061323521843800_jiae010-B14","doi-asserted-by":"crossref","first-page":"e01216-21","DOI":"10.1128\/AAC.01216-21","article-title":"Impact of HIV-1 resistance-associated mutations on susceptibility to doravirine: analysis of real-world clinical isolates","volume":"65","author":"Asante-Appiah","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061323521843800_jiae010-B15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12981-023-00503-5","article-title":"Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance","volume":"20","author":"Rhee","year":"2023","journal-title":"AIDS Res Ther"},{"key":"2024061323521843800_jiae010-B16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/QAI.0000000000002496","article-title":"Review of doravirine resistance patterns identified in participants during clinical development","volume":"85","author":"Martin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024061323521843800_jiae010-B17","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061323521843800_jiae010-B18","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1128\/AAC.01505-10","article-title":"Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C","volume":"55","author":"Armstrong","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061323521843800_jiae010-B19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1128\/AAC.44.3.794-797.2000","article-title":"Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I\/II trial of delavirdine monotherapy (ACTG 260)","volume":"44","author":"Demeter","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061323521843800_jiae010-B20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/ciaa822","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate (TDF) versus efavirenz\/emtricitabine\/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD noninferiority trial","volume":"73","author":"Orkin","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae010\/56609895\/jiae010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/6\/1796\/58211643\/jiae010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/6\/1796\/58211643\/jiae010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T13:38:15Z","timestamp":1718372295000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/6\/1796\/7516255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,1,11]]},"published-print":{"date-parts":[[2024,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae010","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2024,6,15]]},"published":{"date-parts":[[2024,1,11]]}}}